Contact
QR code for the current URL

Story Box-ID: 835140

BIOTRONIK Woermannkehre 1 12359 Berlin, Germany http://www.biotronik.com
Contact Ms Manuela Schildwächter +49 30 689051414
Company logo of BIOTRONIK
BIOTRONIK

Physicians Discuss Latest Cardiac Rhythm Research at 10th International Expert Meeting of Cardiologists in Berlin

(PresseBox) (Berlin, Germany, )
For the tenth year in a row, the Berlin medical technology manufacturer BIOTRONIK is hosting the “Expert Meeting Berlin” (EMB) on January 27 and 28. Led by Dr. Christopher Piorkowski, Heart Center Dresden, Germany, the platform allows cardiologists and electrophysiologists to discuss challenges and opportunities to individualize cardiac rhythm management for patients with atrial fibrillation and heart failure.

A Call for Integrated Therapy

Patients often have both atrial fibrillation and heart failure, which are among the world’s most common conditions. Globally, 33 million people suffer from atrial fibrillation1 and 23 million from heart failure2; figures that are expected to increase. Both conditions are complex and thus extremely challenging to treat. Affected patients require personalized therapy.

“A lot goes in to treatment decisions, including managing heartrate and rhythm, assessing risks from medication and comorbidities, and genetic factors. Not all patients benefit equally from a single treatment approach,” explains Dr. Piorkowski. “It’s been a long time since atrial fibrillation and heart failure were seen as only affecting heart rhythm. Rather, they have complex symptoms and pose an increased risk of early mortality, stroke or repeat hospitalization.”

Numerous diagnostic and therapy options can treat atrial fibrillation and heart failure. “Giving patients the best treatment requires the various disciplines to work together and tailor their approach to individual patients,” notes Dr. Dietmar Bänsch, Clinic for Rhythmology and Electrophysiology in Güstrow, Germany.

The European Society of Cardiology’s 2016 update of its guidelines on atrial fibrillation is an indicator of the move towards interdisciplinary care. For the first time, the guidelines recommend that AF heart teams include specialists from different fields, such as cardiac surgeons and neurologists.3

Accurate Diagnostics and Continuous Monitoring are Essential to Personalized Therapy

Reliable diagnostics and monitoring that optimally detect pathophysiological heart characteristics and prognostic factors are a high priority in a tailored, interdisciplinary therapy strategy.

“There is great potential in new imaging techniques, such as MRI and 3D mapping systems, that combine anatomical and electrical information,” adds Dr. Bänsch. “Together with modern catheters, they make it possible for us to completely restore the heart’s anatomical structures and electrical activity, and to assess these factors individually. In turn, we can better understand complex interactions and perhaps even identify the cause of a rhythm disturbance.”

Cardiac rhythm monitoring is crucial to successful therapy. Clinically confirmed benefits have led the European treatment guidelines to include the continuous remote follow-up of patients with cardiac devices.4 Patients with an increased risk of sudden cardiac death or stroke of an unknown cause particularly benefit from the early detection of potentially life-threatening rhythms.

“The IN-TIME study demonstrated that daily remote patient follow-up with BIOTRONIK Home Monitoring® can reduce the mortality rate in heart failure patients by more than 50 percent. Comparing studies that used systems from other manufacturers, it is clear that the systems differ significantly. Only BIOTRONIK Home Monitoring demonstrates these positive effects,” comments Roberto Belke, Managing Director, BIOTRONIK Germany. “This is also due to our system’s reliable data transmission and the ensuing continuity in patient care.”

References:

1 Chugh S et al. Circulation. 2014, 129.

2 Roger V. Circ Res. 2013, 113.

3 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS.

4 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy. European Heart Journal. 2013, 34.

Website Promotion

Website Promotion

BIOTRONIK

A global leader in cardio- and endovascular medical technology, BIOTRONIK is headquartered in Berlin, Germany, and represented in over 100 countries. Several million patients have received BIOTRONIK implants designed to save and improve the quality of their lives, or have been treated with BIOTRONIK coronary and peripheral vascular intervention products. Since its development of the first German pacemaker in 1963, BIOTRONIK has engineered many innovations, including Magmaris, the first clinically-proven resorbable magnesium scaffold; BIOTRONIK Home Monitoring®; Pulsar, the world’s first 4 F compatible stent for treating long lesions; Orsiro, the industry’s first hybrid drug-eluting stent; and the world’s first implantable cardioverter defibrillators and heart failure therapy devices with ProMRI® technology.

For more information, visit: www.biotronik.com
Twitter: @BIOTRONIK_News
LinkedIn: www.linkedin.com/...

The publisher indicated in each case (see company info by clicking on image/title or company info in the right-hand column) is solely responsible for the stories above, the event or job offer shown and for the image and audio material displayed. As a rule, the publisher is also the author of the texts and the attached image, audio and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.
Important note:

Systematic data storage as well as the use of even parts of this database are only permitted with the written consent of unn | UNITED NEWS NETWORK GmbH.

unn | UNITED NEWS NETWORK GmbH 2002–2024, All rights reserved

The publisher indicated in each case (see company info by clicking on image/title or company info in the right-hand column) is solely responsible for the stories above, the event or job offer shown and for the image and audio material displayed. As a rule, the publisher is also the author of the texts and the attached image, audio and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.